UPDATE: Solid Biosciences (SLDB) - RA Capital Doubles Down, and the ATM Quietly Fires
The 13D filer has a name now — and they’re buying into the FDA binary, not trimming around it.
In the March 20 update I flagged a Schedule 13D as the “sharks circling” — an active filer who, in a sub-$1B biotech, usually signals either an activist push or a strategic accumulator. The June 24 amendment resolves the ambiguity: it’s RA Capital Management (Peter Kolchinsky, Rajeev Shah), one of the more discerning dedicated biotech crossovers on the buyside. And they didn’t just sit there. Between June 18 and June 22, they added 2,696,148 shares — and one of those tranches surfaced a new fact: Solid quietly ran an at-the-market (ATM) offering.
The stock is up ~15% from the May 12 close of $7.72 to $8.86 today. This filing is the cleanest read on why.
The Receipts
RA Capital is the 13D filer, now at 11.9% of the class. The reporting group (RA Capital Management, the Healthcare Fund, Kolchinsky, Shah) beneficially owns 12,036,126 shares, plus pre-funded warrants exercisable for up to 8,178,412 additional shares that are currently blocked by a 9.99% beneficial-ownership cap. The implication: this is not an activist with a board-shakeup deck. RA Capital is a fundamentals-driven healthcare specialist that runs concentrated long positions into clinical and regulatory catalysts. Their thesis on SLDB is almost certainly the same thesis I laid out — accelerated approval optionality on SGT-003 plus the AAV-SLB101 capsid platform — and they’re sized accordingly.
Open-market buying at $8.25–$8.35 on June 18. The Fund bought 338,100 shares at a weighted-average $8.30. Why it matters: this is conviction buying in the open tape, above the March private placement price of $5.61 and above the May 12 close. They are paying up, not bottom-fishing.
The ATM tranche on June 22 — and the disclosure inside it. The Fund bought 2,358,048 shares at $8.20 in what the filing calls “an at-the-market offering by the Issuer.” The implication: Solid has been tapping its S-3 shelf via an ATM facility. This was not telegraphed in the Q1 10-Q’s runway narrative. It’s a small incremental raise (~$19.3M at this clearing price, assuming RA took the full tranche), but it confirms that the dilution mechanism I described in March as “the architecture to tap the equity markets” is now live and being worked methodically — not in one big punishing block.
The pre-funded warrant overhang is now visible. RA holds warrants for 8.18M additional shares, exercise blocked until they sit below 9.99%. Why it matters: this is the structural reason RA can keep accumulating common stock without tripping a 13G-to-13D conversion or a HSR filing — the warrants act as a parked position. It also means RA’s economic exposure is closer to 20M shares (~20% on a fully-converted basis) than the 11.9% headline number suggests.
